DNL343
- Generic Name
- DNL343
- Drug Type
- Small Molecule
- CAS Number
- 2278265-85-1
- Background
DNL343 is under investigation in clinical trial NCT05842941 (HEALEY ALS Platform Trial - Regimen G DNL343).
HEALEY ALS Platform Trial - Regimen G DNL343
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 249
- Registration Number
- NCT05842941
- Locations
- 🇺🇸
Healey Center for ALS at Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05006352
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Atrium Health Neurosciences Institute, Charlotte, North Carolina, United States
🇺🇸PPD Orlando, Orlando, Florida, United States
A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04581772
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Grafton, Auckland, New Zealand
HEALEY ALS Platform Trial - Master Protocol
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 1500
- Registration Number
- NCT04297683
- Locations
- 🇺🇸
Neurology Associates, P.C./Somnos Clinical Research, Lincoln, Nebraska, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04268784
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, South Holland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.